ACLX · Arcellx, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | $4.95M | $7.55M | $8.13M | - | $26.03M | $27.38M | $39.26M | - | $14.96M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | - | $35.09M | $37.63M | $50.80M | - | $39.17M | $40.95M | $32.32M | - | $43.81M |
| SG&A | - | $31.64M | $28.65M | $26.23M | - | $20.47M | $21.42M | $22.75M | - | $16.01M |
| Total Operating Expenses | - | $66.72M | $66.28M | $77.03M | - | $59.65M | $62.38M | $55.07M | - | $59.82M |
| D&A | - | - | - | $1.58M | - | - | - | $826.0K | - | - |
| Operating Income | - | ($61.78M) | ($58.73M) | ($68.90M) | - | ($33.62M) | ($34.99M) | ($15.81M) | - | ($44.86M) |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | - | $0 | $29.0K | $0 | - | $223.0K | $341.0K | $0 | - | ($6.0K) |
| Net Income | - | ($55.78M) | ($52.77M) | ($62.27M) | - | ($25.87M) | ($27.20M) | ($7.20M) | - | ($39.34M) |
| EPS - Basic | - | ($0.99) | ($0.94) | ($1.13) | - | ($0.48) | ($0.51) | ($0.14) | - | ($0.81) |
| EPS - Diluted | - | ($0.99) | ($0.94) | ($1.13) | - | ($0.48) | ($0.51) | ($0.14) | - | ($0.81) |
Balance Sheet
| Line item | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $80.26M | $79.00M | $62.34M | $80.86M | $105.68M | $161.85M | $100.03M | $154.57M | $394.58M | $126.12M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $5.58M | $4.20M | $2.08M | $4.37M | $2.10M | $5.99M | $4.87M | $3.10M | $2.62M | $7.18M |
| Current Assets | $462.18M | $472.08M | $463.89M | $554.15M | $599.31M | $587.30M | $530.20M | $588.73M | $716.36M | $491.46M |
| Total Assets | $603.99M | $655.92M | $619.09M | $648.08M | $711.33M | $764.91M | $734.31M | $779.70M | $825.13M | $614.22M |
| Current Liabilities | $104.20M | $118.39M | $121.85M | $112.46M | $125.41M | $137.02M | $88.29M | $107.90M | $118.24M | $173.15M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $201.64M | $215.14M | $226.86M | $231.18M | $256.54M | $281.89M | $247.14M | $283.12M | $339.75M | $348.09M |
| Stockholders' Equity | $402.35M | $440.78M | $392.22M | $416.91M | $454.79M | $483.02M | $487.16M | $496.57M | $485.38M | $266.13M |
| Retained Earnings | ($725.76M) | ($667.65M) | ($611.87M) | ($559.10M) | ($496.83M) | ($449.75M) | ($423.88M) | ($396.68M) | ($389.48M) | ($409.32M) |
Cash Flow
| Line item | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | ($63.15M) | - | - | - | ($31.91M) | - | - |
| Investing Cash Flow | - | - | - | $37.78M | - | - | - | ($206.81M) | - | - |
| Financing Cash Flow | - | - | - | $543.0K | - | - | - | ($2.98M) | - | - |
| CapEx | - | - | - | $780.0K | - | - | - | $6.43M | - | - |
| Free Cash Flow | - | - | - | ($63.92M) | - | - | - | ($38.34M) | - | - |
Ratios
| Metric | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | -1248.3% | -777.4% | -847.6% | - | -129.1% | -127.8% | -40.3% | - | -299.9% |
| EBITDA margin | - | - | - | -828.2% | - | - | - | -38.2% | - | - |
| Net margin | - | -1127.1% | -698.6% | -766.0% | - | -99.4% | -99.3% | -18.3% | - | -263.0% |
| Free cash flow margin | - | - | - | -786.4% | - | - | - | -97.7% | - | - |
| FCF / Net income | - | - | - | 1.03 | - | - | - | 5.33 | - | - |
| R&D / Revenue | - | 709.0% | 498.1% | 624.9% | - | 150.5% | 149.6% | 82.3% | - | 292.9% |
| SG&A / Revenue | - | 639.3% | 379.3% | 322.6% | - | 78.7% | 78.2% | 57.9% | - | 107.1% |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | - | -8.5% | -8.5% | -9.6% | - | -3.4% | -3.7% | -0.9% | - | -6.4% |
| Return on equity | - | -12.7% | -13.5% | -14.9% | - | -5.4% | -5.6% | -1.4% | - | -14.8% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 4.44 | 3.99 | 3.81 | 4.93 | 4.78 | 4.29 | 6.01 | 5.46 | 6.06 | 2.84 |
| Quick ratio | 4.44 | 3.99 | 3.81 | 4.93 | 4.78 | 4.29 | 6.01 | 5.46 | 6.06 | 2.84 |
| Cash ratio | 0.77 | 0.67 | 0.51 | 0.72 | 0.84 | 1.18 | 1.13 | 1.43 | 3.34 | 0.73 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.50 | 1.49 | 1.58 | 1.55 | 1.56 | 1.58 | 1.51 | 1.57 | 1.70 | 2.31 |
| Liabilities / Assets | 0.33 | 0.33 | 0.37 | 0.36 | 0.36 | 0.37 | 0.34 | 0.36 | 0.41 | 0.57 |
| Efficiency | ||||||||||
| Asset turnover | - | 0.01 | 0.01 | 0.01 | - | 0.03 | 0.04 | 0.05 | - | 0.02 |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | 10.5x | 9.4x | 8.7x | - | 9.3x | 6.1x | 7.4x | - | 6.5x |
| P / S | - | 938.7x | 490.1x | 445.9x | - | 172.7x | 107.9x | 93.5x | - | 116.2x |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | -81.0% | -72.4% | -79.3% | - | 74.0% | 91.5% | 119.2% | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | - | -83.8% | -67.8% | -335.8% | - | 25.1% | -18.4% | 48.1% | - | 52.2% |
| Net income growth (YoY) | - | -115.6% | -94.0% | -765.1% | - | 34.2% | -14.0% | 73.7% | - | 57.6% |
| EPS growth (YoY) | - | -106.3% | -84.3% | -707.1% | - | 40.7% | -2.0% | 75.9% | - | 97.7% |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | -66.7% | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -11.5% | -8.7% | -19.5% | -16.0% | -6.3% | 81.5% | 65.9% | 63.5% | 136.8% | 12.6% |
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Arcellx against the 5 most active filers in the same SIC group.